Search

Additional file 1: Supplementary Methods S1. Details of the study protocol; Supplementary Methods S2. Details of the systematic search.

Supplemental material, sj-docx-1-tag-10.1177_17562848231177151 for Microscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis by Anett Rancz, Brigitta Teutsch, Marie Anne Engh, Dániel Sándor Veres, László Földvári-Nagy, Bálint Erőss, Nóra Hosszúfalusi, Márk Félix Juhász, Péter Hegyi and Emese Mihály in Therapeutic Advances in Gastroenterology

Additional file 2: Table S1. PRISMA checklist 2020; Table S2. Definitions of gut microbiome diversity outcomes reported in the included studies; Table S3. The summarized results of taxonomic analysis of microbiome composition as measured immediately at the end of simultaneous antibiotic and probiotic treatment; Table S4. Outcomes of follow-up as reported in each study; Table S5. Risk of bias assessment for all outcomes - Assignment to intervention; Table S6. Risk of bias assessment for all outcomes - Adhering to intervention; Table S7. GRADE assessment for the meta-analyses of Shannon, Chao1 and Observed OTUs diversity indices.

Supplemental material, sj-docx-1-tag-10.1177_17562848231177151 for Microscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis by Anett Rancz, Brigitta Teutsch, Marie Anne Engh, Dániel Sándor Veres, László Földvári-Nagy, Bálint Erőss, Nóra Hosszúfalusi, Márk Félix Juhász, Péter Hegyi and Emese Mihály in Therapeutic Advances in Gastroenterology

Despite a good knowledge that has been gained on clinicopathological features of COVID-19, less clear information is available on laboratory abnormalities and, especially, on the potential abnormalities of hematological parameters. Several studies have shown that increased levels of pro-inflammatory cytokines, decreased number of lymphocytes especially CD8+ cells, decrease neutrophil and platelet counts were associated with more severe pulmonary inflammation and extensive lung damage in SARS-CoV, MERS-CoV, and in COVID-19. However, little is known about the exact mechanism and the clinical importance of these laboratory changes. In this meta-analysis, we aim to explore the significance of changes in the hematological parameters of patients and assessed the correlation between clinical laboratory data and the severity of COVID-19 in adult patients. We aim to evaluate the predictive value of clinical laboratory data for the severity and mortality of COVID-19 and for intensive care requirement of these patients.

Background and Aims: Pancreatic ductal adenocarcinoma has one of the worst prognosis of all malignancies. This investigated the relationship between the preoperative serum carbohydrate antigen 19-9 and surgical resectability.Methods: A systematic search was performed in three databases (MEDLINE, EMBASE, and Web of Science) to compare the surgical resectability of pancreatic ductal adenocarcinoma in patients with high and low preoperative serum carbohydrate antigen 19-9 values. The receiving operating characteristic curves were constructed and the weighted mean differences for preoperative serum carbohydrate antigen 19-9 levels of resectable and unresectable groups of patients were calculated. The PROSPERO registration number is CRD42019132522.Results: Results showed that there was a significant difference in resectability between the low and high carbohydrate antigen 19-9 groups. Six out of the eight studies utilised receiver operating characteristic curves in order to find the cut-off preoperative carbohydrate antigen 19-9 levels marking unresectability. The overall result from the pooled area under curve values from the receiver operating characteristic curves was 0.794 (CI: 0.694–0.893), showing that the preoperative carbohydrate antigen 19-9 level is a “fair” marker of resectability. The result of the pooled weighted mean differences was 964 U/ml (p < 0.001) showing that there is a significant carbohydrate antigen 19-9 difference between the resectable and unresectable groups. Based on the results of the I-squared test, the result was 87.4%, accounting for “considerable” heterogeneity within the population.Conclusion: Carbohydrate antigen 19-9 is not a reliable marker of unresectability, it should not be used on its own in surgical decision-making.

BackgroundIn pediatric acute pancreatitis (AP), a family history of pancreatic diseases is prognostic for earlier onset of recurrent AP (ARP) and chronic pancreatitis (CP). No evidence supports the same association in adult-onset pancreatitis. Age-specific reasons for familial aggregation are also unclear. We aimed to examine the prognostic role of pancreatic family history for ARP/CP and observe possible underlying mechanisms.MethodsWe conducted a secondary analysis of the Hungarian Pancreatic Study Group’s (HPSG) multicenter, international, prospective registry of patients with AP, both children and adults. We compared the positive family history and the negative family history of pancreatic diseases, in different age groups, and analyzed trends of accompanying factors. Chi-square and Fisher exact tests were used.ResultsWe found a higher rate of ARP/CP in the positive pancreatic family history group (33.7 vs. 25.9%, p = 0.018), peaking at 6–17 years. Idiopathic AP peaked in childhood in the positive family history group (75% 0–5 years) and was consistently 20–35% in the negative group. A higher rate of alcohol consumption/smoking was found in the positive groups at 12–17 years (62.5 vs. 15.8%, p = 0.013) and 18–29 years (90.9 vs. 58.1%, p = 0.049). The prevalence of diabetes and hyperlipidemia steadily rose with age in both groups.ConclusionPositive family history most likely signifies genetic background in early childhood. During adolescence and early adulthood, alcohol consumption and smoking emerge—clinicians should be aware and turn to intervention in such cases. Contrary to current viewpoints, positive pancreatic family history is not a prognostic factor for ARP and CP in adults, so it should not be regarded that way.

Additional file 1. Information collected form each study, additional information used. Figure S1. Geometry of the network and included studies for the analysis of 1-month overall survival. Figure S2. League table of 1-month overall survival. Figure S3. Cumulative ranking curves and SUCRA values for 1-month overall survival. Figure S4. Rankograms for 1-month overall survival. Figure S5. Geometry of the network and included studies for the analysis of 3-month transplant-free survival. Figure S6. League table of 3-month transplant-free survival. Figure S7. Ranking of treatments for 3-month transplant-free survival. Figure S8. Rankograms for 3-month transplant-free survival. Figure S9. Geometry of the network and included studies for the analysis of 1-month transplant-free survival. Figure S10. League table of 1-month transplant-free survival. Figure S11. Ranking of treatments for 1-month transplant-free survival. Figure S12. Rankograms for 1-month transplant-free survival. Figure S13. Risk of bias assessment for overall survival. Figure S14. Risk of bias assessment for transplant-free survival. Table S1. Quality of evidence. Table S2. Assessment of hepatic encephalopathy in the included studies. Table S3. Assessment of bilirubin reduction in the included studies. Table S4. Assessment of ammonia reduction in the included studies. Table S5. Assessment of creatinine reduction in the included studies. Figure S15. Forrest plots for 3-month overall survival. Figure S16. Forrest plots for 1-month overall survival. Figure S17. Forrest plots for 3-month transplant-free survival. Figure S18. Forrest plots for 1-month transplant-free survival. Figure S19. Funnel plot and Egger’s test for 3-month overall survival. Figure S20. Funnel plot and Egger’s test for 1-month overall survival. Figure S21. Cummulative ranking curves and SUCRA for methodology-based evaluation. Figure S22. Methodology-based evaluation league tables.

Supplemental material, sj-docx-1-tag-10.1177_17562848211038772 for Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials by Brigitta Teutsch, Eszter Boros, Szilárd Váncsa, Alex Váradi, Levente Frim, Szabolcs Kiss, Fanni Dembrovszky, Zsuzsanna Helyes, Sarlós Patrícia, Hegyi Péter and Bálint Erőss in Therapeutic Advances in Gastroenterology

Additional file 3.

Additional file 2.

Additional file 1.

Additional file 4.

ObjectiveThe goal of treatment in ulcerative colitis (UC) is to induce and maintain remission. The addition of granulocyte and monocyte apheresis (GMA) to conventional therapy may be a promising therapeutic alternative. In this meta-analysis, we aimed to assess the efficacy and safety profile of GMA as an adjunctive therapy.DesignSystematic review and meta-analysis.MethodsWe searched four databases (MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials) for randomised or minimised controlled trials which discussed the impact of additional GMA therapy on clinical remission induction and clinical remission maintenance compared with conventional therapy alone. Primary outcomes were clinical remission induction and maintenance, secondary outcomes were adverse events (AEs) and steroid-sparing effect. ORs with 95% CIs were calculated. Trial Sequential Analyses were performed to adjusts for the risk of random errors in meta-analyses.ResultsA total of 11 studies were eligible for meta-analysis. GMA was clearly demonstrated to induce and maintain clinical remission more effectively than conventional therapy alone (598 patients: OR: 1.93, 95% CI 1.28 to 2.91, p=0.002, I2=0.0% for induction; 71 patients: OR: 8.34, 95% CI 2.64 to 26.32, p2=0.0% for maintenance). There was no statistically significant difference in the number of AEs (OR: 0.27, 95% CI 0.05 to 1.50, p=0.135, I2=84.2%).ConclusionGMA appears to be more effective as an adjunctive treatment in inducing and maintaining remission in patients with UC than conventional therapy alone.PROSPERO registration numberCRD42019134050.